Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Cantargia in connection with the sale of immunology program CAN10
Mandate

Vinge advises Cantargia in connection with the sale of immunology program CAN10

July 21, 2025

Vinge advises Cantargia AB (publ) in connection with the sale of its early-clinical stage IL1RAP immunology program CAN10 to the Japanese healthcare company Otsuka Pharmaceutical.

Upon closing of the transaction, Cantargia will receive a USD 33 million upfront cash payment, and Cantargia is eligible to up to an additional USD 580 million in milestone payments. Cantargia is also entitled to up to double digits tiered earn-out payments from global product sales.

The Vinge team includes Sofie Nordgren, Christian Lindhé, Martin Madsen Svanberg and Carolina Lundh.

Related

Vinge has advised management of atNorth in connection with the sale of atNorth to CPP Investments and Equinix

 Vinge has advised management of atNorth on the sale of atNorth to Canada Pension Plan Investment Board (CPP Investments) and Equinix (EMEA) Management, Inc. from Partners Group and the minority shareholders.
March 02, 2026

Vinge advises Smart Eye on acquisition of Sightic Analytics

 Smart Eye has entered into an agreement to acquire all shares in Sightic Analytics for a fixed purchase price of SEK 60.5 million, to be paid with newly issued shares in Smart Eye, and an additional purchase price of up to SEK 50 million, conditional upon certain financial and operational targets being met.
February 24, 2026

Vinge advises Axcel and Accru Partners in connection with the acquisitions of Baker Tilly Uppsala AB and Baker Tilly Guide AB

Vinge has advised Axcel VII and Accru Partners in connection with the acquisitions of Baker Tilly Uppsala AB and Baker Tilly Guide AB.
February 22, 2026